Letrozole-induced reversible acute heart failure

IF 1 4区医学 Q4 ONCOLOGY

Journal of Oncology Pharmacy Practice Pub Date : 2024-09-14 DOI:10.1177/10781552241284908

Serhat Sekmek, Dogan Bayram, Ismet Seven, Perihan Perkin, Oznur Bal, Efnan Algin

{"title":"Letrozole-induced reversible acute heart failure","authors":"Serhat Sekmek, Dogan Bayram, Ismet Seven, Perihan Perkin, Oznur Bal, Efnan Algin","doi":"10.1177/10781552241284908","DOIUrl":null,"url":null,"abstract":"IntroductionLetrozole is an aromatase inhibitor (AI), which suppresses plasma estrogen levels by inhibiting the aromatase enzyme, that causes the conversion of androgens to estrogen in peripheral tissues. There is very few information in the literature regarding the development of acute heart failure after AI use. We would like to report a case of a patient who was started letrozole for hormonal treatment and developed acute heart failure due to this.Case reportFifty-seven-year-old woman with hormone positive breast cancer was operated after neoadjuvant chemotherapy and received radiotherapy. Letrozole treatment was initiated after radiotherapy and the patient presented to the emergency department after two weeks with cough and dyspnea. Ejection fraction decreased to 20% and acute heart failure developed.Management and outcomeLetrozole treatment was stopped. Afterwards, improvement in the patient's cardiac functions was observed. Letrozole-induced heart failure was thought to be reversible.DiscussionLetrozole is one of the most commonly used HT in the treatment of hormone positive breast cancer. It may rarely cause cardiac side effects. It is very important to make patients aware of these issues and to be consulted by cardiology in case of possible cardiac symptoms.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552241284908","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

IntroductionLetrozole is an aromatase inhibitor (AI), which suppresses plasma estrogen levels by inhibiting the aromatase enzyme, that causes the conversion of androgens to estrogen in peripheral tissues. There is very few information in the literature regarding the development of acute heart failure after AI use. We would like to report a case of a patient who was started letrozole for hormonal treatment and developed acute heart failure due to this.Case reportFifty-seven-year-old woman with hormone positive breast cancer was operated after neoadjuvant chemotherapy and received radiotherapy. Letrozole treatment was initiated after radiotherapy and the patient presented to the emergency department after two weeks with cough and dyspnea. Ejection fraction decreased to 20% and acute heart failure developed.Management and outcomeLetrozole treatment was stopped. Afterwards, improvement in the patient's cardiac functions was observed. Letrozole-induced heart failure was thought to be reversible.DiscussionLetrozole is one of the most commonly used HT in the treatment of hormone positive breast cancer. It may rarely cause cardiac side effects. It is very important to make patients aware of these issues and to be consulted by cardiology in case of possible cardiac symptoms.

查看原文本刊更多论文

来曲唑诱发的可逆性急性心力衰竭

导言：来曲唑是一种芳香化酶抑制剂（AI），它通过抑制芳香化酶来抑制血浆中的雌激素水平，而芳香化酶会导致外周组织中的雄激素转化为雌激素。有关使用 AI 后出现急性心力衰竭的文献资料很少。我们想报告一例开始使用来曲唑进行激素治疗的患者，她因此出现了急性心力衰竭。病例报告五十七岁的女性激素阳性乳腺癌患者在新辅助化疗后接受了手术和放疗。放疗后开始来曲唑治疗，两周后患者因咳嗽和呼吸困难到急诊科就诊。射血分数降至 20%，出现急性心力衰竭。随后，患者的心脏功能有所改善。讨论来曲唑是治疗激素阳性乳腺癌最常用的激素之一。来曲唑是治疗激素阳性乳腺癌最常用的激素类药物之一，很少会引起心脏副作用。让患者意识到这些问题并在可能出现心脏症状时咨询心脏科是非常重要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oncology Pharmacy Practice Medicine-Oncology

CiteScore

2.70

自引率

7.70%

发文量

276

期刊介绍： Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...